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Abstract
Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of
single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS),
following reports of substantial activity using this schedule of etoposide administration as first-line treatment in
combination with ifosfamide.
Patients This was an open phase I/II trial performed at a single institution in patients with metastatic or locally
advanced STS who had failed first-line treatment with doxorubicin + ifosfamide combination chemotherapy or, less
commonly, single-agent treatment with doxorubicin or ifosfamide. Etoposide was given as a continuous intravenous
infusion over 72 h. The starting dose level was 200 mg m-
2 day- X 3 escalating in 10% steps in cohorts of three patients
until dose-limiting toxicity was encountered.
Results. Seventeen patients were treated, median age 47 years (range 26-71 years). No responses were seen in 16
assessable patients despite etoposide levels in the cotoxic range. The steady-state plasma concentration exceeded
8 #g ml-1 in all patients and in patients treated at > 600 mg m -2 the mean steady-state level was 14.4 #g ml-1. The
median event-free survival was 6 weeks (95% confidence interval (CI) 3.31-8.69) and the overall survival 16 weeks (95%
CI 9.28-22.72). The maximum tolerated dose in this pretreated patient group was 200 mg m-
day -1 3. The
dose-limiting toxicity was myelosuppression.
Discussion. Etoposide given by 72-h infusion is inactive as second-line chemotherapy in STS. It is associated with
significant toxicity when given in these doses, in this patient group.
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Introduction
Etoposide (VP-16-213) is a semi-synthetic deriva-
tive of podophyllotoxin. It first underwent clinical
trials 20 years ago. It has significant activity in
lymphoma, leukaemia and small cell lung cancer
and is included in most standard regimens for the
treatment of germ cell tumours. It acts primarily by
inhibition of topoisomerase II resulting in double-
and single-strand DNA breaks.
The initial trials of etoposide as a single agent in
the treatment of soft tissue sarcoma (STS), almost
all carried out in pretreated patients, have been
disappointing. Welt et al. reported a dose escalation
study in pretreated patients with a 3-day alternating
schedule.
2 The starting dose was 120 mg m-2 given
intravenously every other day for three doses,
repeated every 3 weeks, increasing to a maximum of
240 mg m- per dose. While toxicity was low, there
was only one minor response, which included com-
plete resolution of lung metastases, and 4/26
patients had stable disease. Similarly, a phase II
EORTC study using a treatment schedule of
130 mg m- po daily for 5 days every 3 weeks, in
mostly heavily pretreated patients, reported only one
partial response (PR), which lasted 19 months, in
29 patients.
3
However, responses have been reported using
more prolonged exposure. Hainsworth et al.4 per-
formed a phase I study with daily oral etoposide at
50 mg mg- for 21 days. Seventeen patients with
refractory disease were treated, there were five PRs
lasting 4 months including 2/3 patients with STS.
Kampe et al. investigated a more prolonged oral
treatment regimen but reported no responses in 15
patients treated using 150 mg m- po daily for 15
days. No patient received more than two courses.
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Three phase II studies performed using a schedule a
schedule identical to that of Hainsworth et al., i.e.
50 mg m-2 21 days every 28 days, failed to show
significant activity.6-8
Etoposide has a schedule-dependent mechanism of
action, as elegantly demonstrated by Slevin et al. in
small cell lung cancer.
9 This study compared the
activity of 5 daily 2-h infusions with the same total
dose given as a continuous intravenous infusion over
24 h. The 5-day course was significantly superior with
a response rate of 89% vs 10% despite the area under
the concentration time curve (AUC) being identical
for both schedules. However, when treatment dur-
ation was extended to 8 days, no additional benefit
was seen compared with 5 days,1 and a 15-day
infusion study had to be stopped early because of a
worse response in the 15-day arm.
11 Thompson et al.
performed a study using a protracted intravenous
infusion of etoposide. This study, carried out in
patients with potentially etoposide-sensitive malig-
nancies, was performed at doses of 18-25 mg m-
day
-1 for 21-153 days.
12 The median duration of
treatment was 17 weeks (range 3-80 weeks) and the
overall response rate was 47%. The mean serum
etoposide concentration was 0.7 __
0.42 #g m-1 and
antitumour activity was observed with levels from 0.5
to 1.0 #g m- 1. This was lower than the effective level
suggested by Clark et al.1 in relation to small cell
lung cancer, who reported that serum etoposide levels
> 1 #g m- were associated with antitumour activity
and levels > 3 #g m-1 with haematological toxicity.
This is consistent with the model of a therapeutic
window for etoposide with both the cytotoxicity and
haematological toxicity thresholds falling as the
duration of exposure increases.
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The Scandinavian Sarcoma Group reported a
study of first-line chemotherapy in STS using
etoposide by 72-h continuous infusion (200 mg
m- day- 1) plus ifosfamide 1.5 g m- 2 day- by 2-h
infusion daily 3.14 They reported a PR rate of
40% in 33 patients with a median time to pro-
gression of 8 months. Confidence intervals (CIs)
were not given but were presumably quite wide.
Nevertheless, this level of activity suggests that
etoposide may be active when given by 72-h
infusion, given that response rates for single-agent
ifosfamide at a standard dose of 5 g m-2 have been
in the region of 250/0.15 Evaluation of this schedule
of etoposide as a single agent as second-line treat-
ment in STS seemed warranted.
Patients and methods
Eligibility criteria
The following entry criteria were required: (1) histo-
logical evidence of STS; the following tumour types
were excluded: Ewing’s sarcoma, embryonal or alve-
olar rhabdomyosarcoma, osteosarcoma and malig-
nant mesothelioma; (2) at least one bidimensionally
measurable lesion with evidence of progression
within 6 weeks prior to treatment, (3) white blood
count (WBC) > 3.0 109/1 and platelets
> 100 109/1; (4) WHO performance status 0-2;
(5) age 15-75 years; (6) expected prognosis> 12
weeks; (7) effective contraception for both sexes; (8)
informed consent and expected cooperation during
follow-up. Prior treatment with doxorubicin and/or
ifosfamide was allowed but not required. Exclusion
criteria were: (1) radiotherapy to the sole index
lesion; (2) known central nervous system metas-
tases; (3) second primary malignant disease other
than adequately treated in situ carcinoma of the
cervix or basal or squamous cell carcinoma of the
skin; (4) pregnant or lactating women. Written
informed consent was obtained from all patients and
the study was approved by the local Research Ethics
Committee.
Treatment schedule
Etoposide was given as a 72-h continuous intra-
venous (iv) infusion every 3 weeks. In this pre-
treated patient group, we intended to define the
maximum tolerated dose (MTD) of etoposide for
this schedule. Cohorts of three patients were treated
at each dose level until the MTD was reached.
Blood counts were performed weekly. Dose-limiting
toxicity was defined as grade IV neutropenia for 7 or
more days or grade IV thrombocytopenia of any
duration. The maximum tolerated dose was defined
as that dose causing dose-limiting toxicity in > 60%
of patients. If one patient experienced grade IV
neutropenia for more than 7 days or grade IV
thrombocytopenia, then an additional two patients
were treated at that dose level. If two or more
patients experienced dose-limiting toxicity, then all
subsequent patients were treated at the next lower
-2 dose level. The initial dose was set at 200 mg m
day-1 for 3 days; subsequent dose levels were to be
220 and 240 mg m-
day-1. Steady-state plasma
levels of etoposide were measured on days 2 and 3
of the infusion for the first cycle. In any patient,
treatment was delayed for 1 week if the WBC was
< 2.0 109/1, neutrophil count < 1.0 109/1 or
platelets < 100 109/1 on the day treatment was
due. If treatment had to be delayed by more than 1
week, then subsequent doses were reduced by 20%.
If any treatment cycle was complicated by grade IV
neutropenia and infection, then a similar dose
reduction was employed.
Evaluation
Pretreatment evaluation consisted of clinical history,
physical examination, full blood count, urea and
electrolytes and liver function tests, a chest radio-
graph and a computed tomography (CT) scan.Repeat evaluations of known sites of disease were
performed after two cycles of treatment and there-
after with alternate cycles of treatment. Event-free
survival (EFS) was calculated from the date of study
entry to the date of disease progression or death.
Patients progressing during the first two cycles were
considered as early progression. Toxicity was graded
according to the National Cancer Institute common
toxicity criteria (CTC). Responses were evaluated
according to WHO criteria. 16 The duration of EFS
and overall survival (OS) was estimated by the
Kaplan-Meier method. Evidence of an association
between plasma etoposide levels and haematological
toxicity was assessed by the Pearson correlation
coefficient (using the SPSS statistical package).
Measurement ofplasma etoposide levels
Steady-state plasma etoposide levels were measured
using a high performance liquid chromatography
(HPLC) method, as described by Harvey et al. using
a phenytoin internal standard.
17 Calibration was
achieved in plasma by the external calibration
method using etoposide standards over the range
1-24 #g m-1 vs an internal standard, phenytoin.
Standards were prepared freshly for each HPLC
run. Samples were extracted using dichloromethane,
the organic phase was evaporated to dryness and
reconstituted in methanol-water (51 "49) and cen-
trifuged at 300 g before loading on to the
autosampler.
Results
A total of 17 patients were treated with a total of 44
cycles of chemotherapy (median 2, range 1-5).
Patient characteristics are detailed in Table 1. All
patients had received one line of prior chemo-
therapy, most commonly a combination of ifos-
famide and doxorubicin as part of an EORTC study
in which ifosfamide was given at 5 g m -z, and
doxorubicin at either 50 or 75 mg m -2, the latter
dose supported by granulocyte-macrophage colony-
stimulating factor (BM-CSF). Single-agent doxoru-
bicin was given to three patients at 75 mg m-2 and
a combination of doxorubicin with ifosfamide at 5-
9 g m-2 to two patients. Three patients were ini-
tially treated elsewhere, two received doxorubicin
and one epirubicin. Two patients had received two
prior chemotherapy regimens. All 17 patients were
assessable for toxicity, 16 were assessable for
response and one patient died due to neutropenia-
related infection prior to any response assessment.
One patient withdrew from the study after two
courses with stable disease and subsequently
received four more courses of etoposide off study.
He currently remains alive with stable disease. The
initial dose level was 200 mg m-2 day-1 for 3 days;
four patients were treated at this dose before escalat-
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ing to a dose level of 220 mg m-2 day-1 for 3 days.
Five patients were treated at this dose but toxicity
proved unacceptable and the remaining eight
patients were treated at the lower dose level. Despite
this, five patients required dose reductions (four at
200 mg m- day- and one at 220 mg m- day- 1).
Response
No responses were seen. Eight patients had stable
disease and eight patients progressed through
chemotherapy. The median EFS was only 6 weeks
(95% CI 3.31-8.69) and the median OS was 16
weeks (95% CI 9.28-22.72) (Fig. 1). In the eight
patients with stable disease the median progression-
free survival was 3.5 months. Of the other two
surviving patients, one subsequently received
abdominal radiotherapy resulting in a PR. She has
subsequently progressed with hepatic metastases,
while the other has had no further therapy.
Plasma etoposide concentrations
Data were available on 12 patients and 70 courses.
Where steady-state levels at two time points during
Table 1. Patient characteristics
Parameter Number of patients
Registered 17
Assessable for response 16
Assessable for toxicity 17
Age
Median 47
Range 26-71
Sex
Male 10
Female 7
Performance status (WHO)
0
12
2 4.
Histology
Leiomyosarcoma 8
Liposarcoma 3
Malignant peripheral nerve sheath 2
Synovial sarcoma
Malignant fibrous histiocytoma
Uterine leiomyosarcoma
High grade not classified
Grade
Low 6
Intermediate
High 8
Not known 2
Prior chemotherapy 17
Response to prior chemotherapy
Progression 3
Stable disease 11
Partial response 2152 C.R. Crawley et al.
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Fig. 1. Overall survival in patients with recurrent STS
treated with 72-h etoposide..
the 72-h infusion were measured, the mean plasma
level has been calculated (16/20). The results are
shown in Tables 2 and 3. All concentrations were
above those previously reported as the cytotoxic
threshold.TM There was no clear association
between plasma level and CTC grade haematologi-
cal toxicity (Fig. 2) (r-0.29, p=0.26) and there
was no significant correlation between dose and
mean plasma level (r 0.28, p 0.24) (Table 2).
Toxicity
Toxicity was significant and primarily haematologi-
cal. Data were available on 17 patients and for 95%
of the treatment cycles. The majority, i.e. 76%, of
patients experienced grade IV neutropenia. Throm-
bocytopenia was less of a problem with grade IV
toxicity in only one patient. Blood transfusions were
required in 47% of patients. Growth factor support
Table 2. Plasma etoposide concentration
Mean
Treatment Dose etoposide level
Patient cycle (mg m-2) (mg ml-1)
2 480 8.7
2 2 528 9.3
3 600 8.3
4 600 13.9
4 2 600 12.3
5 600 16.8
6 600 20.0
6 3 600 23.1
7 2 600 8.8
8 2 600 22.9
9 600 9.2
10 2 600 11.8
10 3 600 14.3
10 600 14.4
11 600 11.5
11 660 8.3
11 3 660 21.6
12 660 14.1
12 660 14.2
12 2 660 14.1
Table 3. Mean etoposide concentration vs
dose
Dose
(mg m
< 600
600
660
Mean concentration
(#g ml-1 -+. SD)
9.0 (0.4)
14.4 (4.2)
14.5 (4.7)
(Correlation coefficient r 0.28, p 0.24).
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Fig. 2. Haematological toxicity vs mean plasma etoposide
levels (correlation coefficient r 29, p 0.26).
was not used. Three patients died on treatment, one
from Escherichia coli sepsis when neutropenic, one at
home from an acute abdominal catastrophe during
her third course, her disease having been stable after
the second course. She had a normal blood count at
the time of the last chemotherapy 6 days before her
death. The third patient died due to progressive
pulmonary disease but was neutropenic at the time
of his death. Early progression was seen in two
additional patients who both received only one
course of treatment. Seven patients were admitted
for neutropenic sepsis. Other admissions (total
three) were for problems related to disease pro-
gression. Non-haematological toxicity was less of a
problem. Two patients (11%) experienced grade III
emesis and one patient developed pulmonary
oedema due to the fluid load. Alopecia was almost
universal but mostly predated etoposide The
remaining toxicities were relatively mild and
included mucositis in seven patients (grade 1-2),
diarrhoea in three patients (grade 2), fatigue and
asymptomatic elevation of liver enzymes.
Discussion
In this study, 17 patients with recurrent STS were
treated with a continuous infusion of etoposide. A
dose escalation was planned but was not feasible.
The maximum tolerated dose in this pretreated
patient group was 600 mg m-2. Plasma etoposideconcentrations showed considerable inter-patient
variation (range 8.3-22.9 /g m -1, for patients
receiving 600 mg m-). We were unable to demon-
strate a correlation between neutropenia and
plasma level; however, our starting dose was at the
MTD and 76% of cycles were associated with grade
IV neutropenia. The numbers were insufficient to
show a correlation between plasma concentration
and dose. Overall, the toxicity was significant with
three deaths on treatment. In the 16 assessable
patients, no responses were seen, although stable
disease was observed in eight patients for short
periods. One patient had stable disease for more
than 12 months.
These results are disappointing. Given the lack of
activity of etoposide in either IV bolus or protracted
oral schedules,2’4’6’8 the lack of demonstrable
activity for etoposide in this schedule is likely to
present drug resistance rather than an inactive
schedule. In this setting, it seems unlikely that dose
escalation with cytokine support will produce useful
responses or effective palliation.
It is not possible to determine whether this repre-
sents de novo drug resistance or acquired resistance
after previous doxorubicin/ifosfamide exposure. Of
note, one patient who progressed on etoposide sub-
sequently had a transient response to high-dose
ifosfamide (12 g m-2). It should be noted that this
patient group had unusually refractory disease to
first-line chemotherapy with doxorubicin and/or
ifosfamide chemotherapy with a response rate of
only 12.5% (2/16). This is outside the 95% CI for
doxorubicin alone, doxorubicin/ifosfamide or
CYVADIC in the randomized EORTC study which
compared these three lines of treatment.
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In summary, there is little evidence of activity of
etoposide in any schedule in relapsed or progressive
STS. This study shows that a 72-h etoposide
infusion at the maximum tolerated dose is inactive
in previously treated patients in common with other
reports using slightly different schedules. The 40%
response rate obtained by the Scandinavian Sar-
coma Group
14 with ifosfamide and etoposide as
first-line treatment may reflect genuine etoposide
activity in previously untreated patients or, alterna-
tively, a schedule advantage for fractionated ifos-
famide treatment given that the ifosfamide was
given as three consecutive daily infusions. A recent
randomized phase II study performed by the
EORTC Soft Tissue and Bone Sarcoma Group
demonstrated a markedly higher response rate when
ifosfamide, albeit at a higher total dose, was given
as three daily infusions of 3 g m-2 compared with a
single 24-h infusion of 5 g m-2, i.e. 17% vs 3%.
19
Both response rates were lower than expected for
reasons which are not clear. However, the response
rate in the Scandinavian study remains within the
range of reported response rates for phase II studies
of ifosfamide alone. 14 There is no indication for the
use of etoposide in any regimen in pretreated
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patients and its inclusion in combination regimens
as initial therapy should be evaluated in prospective
randomized trials.
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